Filing Flows › Beta Bionics (BBNX) › Q3 2025
Beta Bionics (BBNX) Q3 2025 earnings results (third quarter 2025)
10-Q filed Oct 28, 2025
Beta Bionics (BBNX) reported revenue of $27.3M for the third quarter 2025 (Q3 2025), +63% from a year earlier and +17% from the quarter before. Operating margin was -62.5%, net loss $14.2M (52.1% of revenue).
Beta Bionics, Q3 2025: revenue $27.3M (+63% year over year), operating margin -62.5%, net loss $14.2M, operating cash flow −$8.7M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $27.3M | +17% | +63% |
| Operating profit | −$17.0M | — | — |
| Net earnings | −$14.2M | — | — |
| Operating cash flow | −$8.7M | — | — |
What changed
Revenue was $27.3M in Q3 2025, up 63% year over year and up 17% from the previous quarter.
Gross margin was 55.5%, up 2.1 points from a year earlier. Operating costs exceeded revenue by $17.0M, an operating margin of -62.5%. Operating expenses grew 62% against revenue growth of 63%. The fastest-growing cost line was Sales & marketing (+66%). The quarter ended with a net loss of $14.2M, narrower than the previous quarter's $16.9M loss.
Operating cash flow was −$8.7M. Non-cash charges added back $385K of depreciation and $4.5M of share-based compensation. Working capital and other items added $617K. Capital expenditures of $1.3M exceeded it, leaving free cash flow of −$10.0M.
Questions
What was Beta Bionics' revenue in the third quarter 2025?
Beta Bionics (BBNX) reported revenue of $27.3M for the third quarter 2025 (Q3 2025), +63% from a year earlier and +17% from the quarter before.
Was Beta Bionics profitable in the third quarter 2025?
Operating loss was $17.0M (-62.5% of revenue) and net loss $14.2M.
Source: Beta Bionics 10-Q on SEC EDGAR.